CA-TIGO
23.1.2024 15:01:31 CET | Business Wire | Press release
Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy storage solutions, today announced the launch of the Tigo GO EV Charger for the German market. A smart charging station for electric vehicles, GO EV Charger offers seamless integration with the Tigo EI Residential solar-plus-storage solution. Available as both a single and three-phase charger up to 22 kW, the GO EV Charger can be wall-mounted indoors or outdoors and includes RFID technology for easy user authentication. With flexible charging modes tailored to accommodate homeowner use cases, the GO EV Charger can be installed and connected to the Tigo EI Inverter in minutes and managed centrally from the Tigo EI monitoring platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240123262185/en/
Available to the German market as a single and three-phase charger, the GO EV Charger offers flexible charging and easy management, tailored to accommodate each homeowner’s unique use case. (Photo: Business Wire)
“The synergy achieved by the integration of the charger with the solar-plus-storage solution marks a significant milestone in the journey towards a future of holistic residential energy systems,” said Klaus Besier, Managing Director at Germany’s Elektrobau Meffert GmbH, one of the first GO EV Charger customers. “As a PV installer, I believe it is crucial to have a comprehensive solution where the components are designed to work together seamlessly for an expeditious installation process. When you add the outstanding Tigo support team, which speaks the installer’s language, and the EI monitoring platform that empowers system owners to match solar energy production with their specific needs proactively, you have a winning combination. Tigo streamlines our ability to deliver more efficient and cohesive systems to more customers.”
With GO EV Charger, the Tigo EI Residential solution provides an efficient renewable energy ecosystem capable of generating, converting, storing, and managing solar energy from the roof down to the everyday needs of homeowners. On the web or through the Tigo EI App, Tigo provides homeowners with sophisticated management tools, and the Tigo Energy Intelligence platform serves as the central management platform for installers to monitor and manage the systems in their portfolios.
“Tigo’s journey first started with technological innovations to make solar safer and more efficient, followed by technologies that increase solar production and reduce operating costs as well as power conversion and energy storage, and the GO EV Charger is a natural next step in this evolution,” said Massimo Migliorini, Director Business Development EMEA – EI at Tigo Energy. “Homeowners have the capacity not only to generate clean and sustainable energy but to intelligently manage, store, and use it in once unimaginable ways. This milestone exemplifies Tigo’s unwavering commitment to renewable energy and giving individuals the power to actively contribute to a cleaner, greener future.”
The release of the GO EV Charger comes on the heels of an introductory webinar scheduled for February 5th. This will be followed by digital and live training events for German PV professionals, hosted with Tigo distribution partners in Germany between February and March. Additionally, the training offered by Tigo Academy – also available in German – will be enhanced by a series of technical content dedicated to the new Tigo solution for e-mobility.
For GO EV Charger ordering information and to get connected with an experienced member of the Tigo team, visit tigoenergy.com/contacts.
About Tigo Energy
Founded in 2007, Tigo is a worldwide leader in the development and manufacture of smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Tigo combines its Flex MLPE (Module Level Power Electronics) and solar optimizer technology with intelligent, cloud-based software capabilities for advanced energy monitoring and control. Tigo MLPE products maximize performance, enable real-time energy monitoring, and provide code-required rapid shutdown at the module level. The company also develops and manufactures products such as inverters and battery storage systems for the residential solar-plus-storage market. For more information, please visit www.tigoenergy.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240123262185/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom